

A Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of Baricitinib in Children from 6 Years & Less than 18 Years of Age with Alopecia Areata

Status: Recruiting

Eligibility Criteria

Sex: Male or Female

Age Group: Up to 18 years old

This study is NOT accepting healthy volunteers

Inclusion Criteria:

- children 6 to 18 years old - at or above the 5th percentile of weight for age - diagnosis of Alopecia Areata (AA) for at least 1 year - current AA episode of at least 6 months duration with hair loss encompassing 50% or more of the scalp - history of trial and failure with at least 1 available treatment - history of psychological counseling related to AA

Exclusion Criteria:

- primarily diffuse type of AA (characterized by diffuse hair shedding) - currently experiencing other forms of alopecia including, but not limited to: trichotillomania, TE, chemotherapy-induced hair loss, or any other concomitant conditions (for example, tinea capitis, psoriasis, lupus erythematosus, or secondary syphilis)

Conditions & Interventions

Conditions:

Dermatology (Skin, Hair & Nails)

Keywords:

AA, Alopecia Areata, hair loss

More Information

Description: We are conducting a research study for children ages 6-17 with patchy Alopecia Areata (AA). The purpose of this research study is to learn more about the safety, tolerability and efficacy of an investigational drug called Baricitinib. This study will compare the investigational drug to a placebo (inactive substance) to see how well the investigational drug works.

Study Contact: Melissa Kelly - kell2061@umn.edu

Principal Investigator: Maria Hordinsky

IRB Number: SITE00001967

Thank you for choosing StudyFinder. Please visit <http://studyfinder.umn.edu> to find a Study which is right for you and contact sfinder@umn.edu if you have questions or need assistance.